Intrinsic Therapeutics, Inc
Medical Equipment Manufacturing • 
Woburn, Massachusetts, United States • 51-100 Employees
Company overview
| Headquarters | 30 Commerce Way, Woburn, Woburn, MA 01801, US |
| Phone number | +18442887474 |
| Website | |
| NAICS | 3391 |
| SIC | 504 |
| Founded | 2000 |
| Employees | 51-100 |
| Socials |
Key Contacts at Intrinsic Therapeutics, Inc
Heather Wozniak
National Sales Director
Brett Sorensen
Regional Sales Director
Jacob Einhorn
Chief Technology Officer And Co-Founder
Jean Fraser
Director Patient Access
Ivan Grzan
Senior Director, Professional Education
Erin Percinsky
National Director, Payor Access
Detlev Lieberz
Associate Director Clinical Affairs
Sue Michalic
Senior Director, Payor Relations
Cary Hagan
Chief Executive Officer
Intrinsic Therapeutics, Inc Email Formats
Intrinsic Therapeutics, Inc uses 3 email formats. The most common is {first initial}{last name} (e.g., jdoe@barricaid.com), used 53.3% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@barricaid.com | 56.6% |
{first name}{last name} | johndoe@barricaid.com | 43.3% |
About Intrinsic Therapeutics, Inc
Adjacent to a lumbar discectomy, the Barricaid® device is designed to close large defects in the annulus, which often lead to disc reherniation and/or disc collapse. Barricaid is a permanent implant with two components - a titanium bone anchor and a flexible polymer barrier. The barrier is designed to prevent reherniation by physically blocking the annulus at the post-surgery defect. The anchor component is comprised of titanium alloy that is placed into either the caudal or cranial-adjacent vertebral body to secure the device in position. The Barricaid has been studied in a definitive – level 1B evidence - randomized superiority trial with over 550 patients enrolled (clinicaltrials.gov NCT01283438). The study focuses on patient at highest risk of reherniation and reoperation, enrolling only those patients with large defects (width >5 mm). The co-primary endpoints of reherniation and an 8-point composite of safety and effectiveness are evaluated at 2 years, with a parallel cost effectiveness analysis. Treated patients were found superior on both endpoints, with significantly lower rates of symptomatic recurrences (12% vs. 25%, p<0.001), index-level reoperations (9% vs. 16%, p=0.01), and device or procedure related serious adverse events (SAEs) (7% vs. 17%, p=0.001). Through two years, a total of 29 reoperations were performed in Barricaid subjects in comparison to 61 procedures in Controls. Study results are published in The Spine Journal, May 2018. Barricaid is FDA-Approved For full risk/benefit, see: www.barricaid.com/instructions-for-use
Intrinsic Therapeutics, Inc revenue & valuation
| Annual revenue | $12,000,000 |
| Revenue per employee | $142,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Medical Equipment Manufacturing industry and current estimated revenues | $38,400,000 |
| Total funding | $116,500,000 |
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Intrinsic Therapeutics, Inc has 35 employees across 7 departments.
Departments
Number of employees
Funding Data
Explore Intrinsic Therapeutics, Inc's funding history, including investment rounds, total capital raised, and key backers.
Intrinsic Therapeutics, Inc Tech Stack
Discover the technologies and tools that power Intrinsic Therapeutics, Inc's digital infrastructure, from frameworks to analytics platforms.
Video players
Form builders
JavaScript libraries
Caching
JavaScript libraries
JavaScript libraries
JavaScript libraries
Miscellaneous
Page builders
JavaScript libraries
Web servers
SEO
South Africa
United Kingdom
Denmark
Frequently asked questions
4.8
40,000 users
